Loading...

ATNM ACTINIUM PHARMACEUTICALS INC US FDA Inspections 8-K Filing

CTNM

TNM

ACTINIUM PHARMACEUTICALS INC

(ATNM)

2024 8-K

Voting Frequency Update

Management Changes

Annual Meeting Results

Director Elections

Director Appointment

Regulatory Update

Election of Class I Directors

Regulation FD Disclosure

Phase 3 SIERRA trial results

External Links:

Actinium Pharmaceuticals, Inc. issued a press release announcing a regulatory update on their planned Biologics License Application (BLA) filing for Iomab-B in patients with active relapsed or refractory acute myeloid leukemia (r/r AML).

AI Assistant

ACTINIUM PHARMACEUTICALS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.